Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod combined with NSAIDs for active axial spondyloarthritis/ankylosing spondylitis
ChiCTR2100043171Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iguratimod in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS), sponsored by Qilu Hospital of Shandong University. Primary endpoint: ASAS20 response rate at 24 weeks. Started Jan 2021; status: recruiting.
02
Drugs
iguratimod
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2100043171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043171.